Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR2 | O43603 | 3/20 | 0.44 |
| ▸ | GALR1 | P47211 | 3/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | SORD | Q00796 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3878777 | 0.90 | GALR2 (0.43) | GALR2GALR1PHGDHTRPV1EPHX2 | |
| SCHEMBL3877797 | 0.85 | GALR2 (0.46) | GALR2GALR1EPHX2 | |
| SCHEMBL3884829 | 0.84 | TRPV1 (0.46) | GALR2GALR1TRPV1 | |
| SCHEMBL3877704 | 0.84 | GALR2 (0.50) | GALR2GALR1TRPV1EPHX2 | |
| SCHEMBL3887718 | 0.84 | GAA (0.46) | GALR2GALR1PHGDHGAATRPV1 | |
| SCHEMBL3878072 | 0.84 | GALR2 (0.59) | GALR2GALR1TRPV1 | |
| SCHEMBL3881411 | 0.84 | TRPV1 (0.45) | GALR2GALR1TRPV1 | |
| SCHEMBL3878717 | 0.83 | GALR2 (0.42) | GALR2GALR1PHGDHGAAEPHX2 | |
| SCHEMBL3888381 | 0.83 | GALR2 (0.61) | GALR2GALR1TRPV1 | |
| SCHEMBL3877905 | 0.83 | GALR2 (0.48) | GALR2GALR1PHGDHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | GALR2 171/4885GALR1 270/4885PHGDH 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.